why microdose glp 1 THE PCCA BLOG Microdosing GLP-1s: Reduce Inflammation, Support

Telogen effluvium is temporary and self-resolving, your hair grows back

Healthier consumption patterns are emerging

Patients with a history of gallstones, previous cholecystitis, or known cholelithiasis on imaging should discuss these conditions with their healthcare provider before starting therapy

Most symptoms improve within 4-8 weeks as the body adjusts to therapy

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Its minimal impact on blood sugar, combined with its sweet taste, makes it a suitable alternative for those following a therapeutic carbohydrate reduction nutrition strategy